CELLphenomics and Charles River announce agreement, expanding 3D in vitro services for cancer therapy drug screening

Berlin, Germany and Wilmington, Mass., Jan. 9, 2024 – CELLphenomics and Charles River Laboratories International, Inc. (NYSE: CRL) announced an agreement, that provides Charles River clients with access to CELLphenomics’ proprietary 3D tumor model platform, PD3D®, which will expand Charles River’s 3D in vitro testing services to further optimize oncological approaches for its clients. CELLphenomics’ core competence is the […]

CELLphenomics, KYAN Technologies and Alentis Therapeutics join forces

Berlin, Singapore, Allschwil 9-29-2023 CELLphenomics and KYAN Technologies, a vanguard combinatory drug development solutions provider, are thrilled to announce a strategic partnership with Alentis Therapeutics, a clinical-stage biopharmaceutical company developing breakthrough treatments for Claudin-1 positive tumours and organ fibrosis. This partnership aims to accelerate research into Claudin-1 expression using innovative patient-derived 3D (PD3D®) cell culture […]

Manuela Regenbrecht

Manuela Regenbrecht is the director of medical affairs at CELLphenomics. She is a medical specialist in internal medicine, hematology and oncology. Born in Berlin, she studied medicine at the Charité Universitätsmedizin Berlin as a scholarship holder from the German Academic Scholarship Foundation. She spend part of the practical year in Nepal.  She completed her subsequent residency […]